Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus short-course chemoradiotherapy as neoadjuvant treatment for locally advanced MSS/pMMR rectal cancer
ChiCTR2300076407Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathologic complete response rate. Started Oct 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2300076407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076407.